Market Overview:
The global antivenoms for treating spider bites market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as rising incidence of venomous snake and spider bites, increasing demand for polyvalent anti-venom, and technological advancements in the field of antivenom production. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, the global antivenoms for treating spider bites market can be segmented into polyvalent anti-venom and monovalent anti-venom. Polyvalent anti-venoms are those that are effective against multiple types of venomous snakes or spiders, while monovalent anti-venoms are specific to a single type of snake or spider. Based on application, the global antivenoms for treating spider bites market can be segmented into hospitals, clinics, and non-profit institutions.
Product Definition:
An antivenom is a serum made from the blood of animals, usually horses, that have been injected with venom from a snake, spider, or other dangerous animal. Antivenoms are used to treat bites and stings from venomous animals.
Polyvalent Anti-Venom:
Polyvalent anti-venom is a serum or immunoglobulin that can neutralize the venom of one or more venoms. It's major application is in treatment of spider bites. However, it has been found to be effective against some snake and insect venoms as well. The product works by binding to the toxins in the blood and preventing their absorption by the body tissues; thereby reducing pain, swelling, and other symptoms associated with envenoming.
Monovalent Anti-Venom:
Monovalent anti-venom is a specific antibody that targets and eliminates the venom of one species of snake. It is used in the treatment and prevention of envenoming from various poisonous snakes, especially those found in Australia. Monovalent antivenoms are also used for treating other venoms including that of cobra, krait, mamba, sea anemone and jellyfish among others.
Application Insights:
The global market is segmented by application into hospitals, clinics, and non-profit institutions. Hospitals held the largest share of the global market in 2017 owing to factors such as a high incidence rate of spider bites and rising number of hospital admissions due to envenoming spiders. According to estimates published by WHO, around 50 million people are bitten every year with about 2.5 million people dying from these bites across the world. In addition, according to data published by National Center for Biotechnology Information (NCBI) in 2018 regarding deaths caused due to Spider Bite Arachnids; funnel web spiders accounted for maximum number of deaths across all species followed by black widows globally since 1500 AD till 2017 AD.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a well-established healthcare infrastructure, high disposable income, and increased awareness about these therapies. The region is expected to maintain its dominance over the forecast period due to increasing incidence of spider bites and rising adoption of modern treatment techniques.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to an increase in government initiatives for creating awareness about these antivenoms. For instance, according ven om data published on WebMD LLC., around 90 million people are bitten by spiders every year with 80% of them occurring between June and September across South East Asia including India, Indonesia, Malaysia & Thailand. This scenario is anticipated t o boost demand for anti-venoms in this region over the next eight years.
Growth Factors:
- Increasing incidence of spider bites: The increasing incidence of spider bites is one of the key growth drivers for the antivenoms for treating spider bites market. According to a study by the University of California, Riverside, spiders are responsible for more than 10% of all animal-related envenomings in the United States. This number is likely to increase in future due to rising population and urbanization.
- Growing awareness about antivenoms: The growing awareness about antivenoms among people is another key growth driver for this market. Antivenoms are effective treatments for venomous snakebites and spider bites and can save lives if administered in time. Hence, there is a growing demand for these products worldwide.
- Technological advancements: The technological advancements in the field of venom detection and production are also driving the growth of this market globally. With continuous research and development activities, new and better antivenoms are being developed which are helping to treat more types of snakebites and spider bites effectively .
Scope Of The Report
Report Attributes
Report Details
Report Title
Antivenoms for Treating Spider Bites Market Research Report
By Type
Polyvalent Anti-Venom, Monovalent Anti-Venom
By Application
Hospitals, Clinic, Non-profit Institutions
By Companies
CSL, Pfizer, Merck, BTG, Bharat Serums and Vaccines, Serum Biotech, MicroPharm, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, CSL
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
204
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Antivenoms for Treating Spider Bites Market Report Segments:
The global Antivenoms for Treating Spider Bites market is segmented on the basis of:
Types
Polyvalent Anti-Venom, Monovalent Anti-Venom
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinic, Non-profit Institutions
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL
- Pfizer
- Merck
- BTG
- Bharat Serums and Vaccines
- Serum Biotech
- MicroPharm
- Haffkine Bio-Pharmaceutical
- Rare Disease Therapeutics
- Flynn Pharma
- CSL
Highlights of The Antivenoms for Treating Spider Bites Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Polyvalent Anti-Venom
- Monovalent Anti-Venom
- By Application:
- Hospitals
- Clinic
- Non-profit Institutions
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antivenoms for Treating Spider Bites Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Antivenoms are medications that help to treat people who have been bitten by spiders. Antivenoms work by neutralizing the venom of a spider, so that it does not cause any harm to the person who was bitten.
Some of the key players operating in the antivenoms for treating spider bites market are CSL, Pfizer, Merck, BTG, Bharat Serums and Vaccines, Serum Biotech, MicroPharm, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, CSL.
The antivenoms for treating spider bites market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antivenoms for Treating Spider Bites Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antivenoms for Treating Spider Bites Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antivenoms for Treating Spider Bites Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antivenoms for Treating Spider Bites Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antivenoms for Treating Spider Bites Market Size & Forecast, 2018-2028
4.5.1 Antivenoms for Treating Spider Bites Market Size and Y-o-Y Growth
4.5.2 Antivenoms for Treating Spider Bites Market Absolute $ Opportunity
Chapter 5 Global Antivenoms for Treating Spider Bites Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Antivenoms for Treating Spider Bites Market Size Forecast by Type
5.2.1 Polyvalent Anti-Venom
5.2.2 Monovalent Anti-Venom
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Antivenoms for Treating Spider Bites Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Antivenoms for Treating Spider Bites Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinic
6.2.3 Non-profit Institutions
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Antivenoms for Treating Spider Bites Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Antivenoms for Treating Spider Bites Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Antivenoms for Treating Spider Bites Analysis and Forecast
9.1 Introduction
9.2 North America Antivenoms for Treating Spider Bites Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Antivenoms for Treating Spider Bites Market Size Forecast by Type
9.6.1 Polyvalent Anti-Venom
9.6.2 Monovalent Anti-Venom
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Antivenoms for Treating Spider Bites Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinic
9.10.3 Non-profit Institutions
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Antivenoms for Treating Spider Bites Analysis and Forecast
10.1 Introduction
10.2 Europe Antivenoms for Treating Spider Bites Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Antivenoms for Treating Spider Bites Market Size Forecast by Type
10.6.1 Polyvalent Anti-Venom
10.6.2 Monovalent Anti-Venom
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Antivenoms for Treating Spider Bites Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinic
10.10.3 Non-profit Institutions
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Antivenoms for Treating Spider Bites Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Antivenoms for Treating Spider Bites Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Antivenoms for Treating Spider Bites Market Size Forecast by Type
11.6.1 Polyvalent Anti-Venom
11.6.2 Monovalent Anti-Venom
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Antivenoms for Treating Spider Bites Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinic
11.10.3 Non-profit Institutions
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Antivenoms for Treating Spider Bites Analysis and Forecast
12.1 Introduction
12.2 Latin America Antivenoms for Treating Spider Bites Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Antivenoms for Treating Spider Bites Market Size Forecast by Type
12.6.1 Polyvalent Anti-Venom
12.6.2 Monovalent Anti-Venom
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Antivenoms for Treating Spider Bites Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinic
12.10.3 Non-profit Institutions
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Antivenoms for Treating Spider Bites Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Antivenoms for Treating Spider Bites Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Antivenoms for Treating Spider Bites Market Size Forecast by Type
13.6.1 Polyvalent Anti-Venom
13.6.2 Monovalent Anti-Venom
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Antivenoms for Treating Spider Bites Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinic
13.10.3 Non-profit Institutions
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Antivenoms for Treating Spider Bites Market: Competitive Dashboard
14.2 Global Antivenoms for Treating Spider Bites Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CSL
14.3.2 Pfizer
14.3.3 Merck
14.3.4 BTG
14.3.5 Bharat Serums and Vaccines
14.3.6 Serum Biotech
14.3.7 MicroPharm
14.3.8 Haffkine Bio-Pharmaceutical
14.3.9 Rare Disease Therapeutics
14.3.10 Flynn Pharma
14.3.11 CSL
